Donanemab in Early Alzheimer’s Disease von Mintun, Mark A, Lo, Albert C, Duggan Evans, Cynthia, Wessels, Alette M, Ardayfio, Paul A, Andersen, Scott W, Shcherbinin, Sergey, Sparks, JonDavid, Sims, John R, Brys, Miroslaw, Apostolova, Liana G, Salloway, Stephen P, Skovronsky, Daniel M

Volltext

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration von Thijssen, Elisabeth H., La Joie, Renaud, Wolf, Amy, Strom, Amelia, Wang, Ping, Iaccarino, Leonardo, Bourakova, Viktoriya, Cobigo, Yann, Heuer, Hilary, Spina, Salvatore, VandeVrede, Lawren, Chai, Xiyun, Proctor, Nicholas K., Airey, David C., Shcherbinin, Sergey, Duggan Evans, Cynthia, Sims, John R., Zetterberg, Henrik, Blennow, Kaj, Karydas, Anna M., Teunissen, Charlotte E., Kramer, Joel H., Grinberg, Lea T., Seeley, William W., Rosen, Howie, Boeve, Bradley F., Miller, Bruce L., Rabinovici, Gil D., Dage, Jeffrey L., Rojas, Julio C., Boxer, Adam L.

Volltext

Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease von Sparks, JonDavid, Lo, Albert C., Evans, Cynthia Duggan, Chatterjee, Saptarshi, Andersen, Scott W., Sims, John R., Brys, Mirek, Mintun, Mark A

Volltext

Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia von Lo, Albert C., Evans, Cynthia Duggan, Mancini, Michele, Wang, Hong, Shcherbinin, Sergey, Lu, Ming, Natanegara, Fanni, Willis, Brian A.

Volltext

TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment von Shcherbinin, Sergey, Andersen, Scott W., Evans, Cynthia Duggan, Lo, Albert C., Lu, Ming, Navitsky, Michael, Collins, Emily C, Sims, John R., Brooks, Dawn A., Mintun, Mark A

Volltext

PLASMA NF-L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE-AD STUDY von Wang, Hong, Charil, Arnaud, Shcherbinin, Sergey, Natanegara, Fanni, Chao, Georgia, Evans, Cynthia Duggan, Dage, Jeffrey, Irizarry, Michael C., Lo, Albert, Sims, John R.

Volltext

IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL von Shcherbinin, Sergey, Hesterman, Jacob, Devous, Michael D., Natanegara, Fanni, You, Wenqi, Evans, Cynthia Duggan, Collins, Emily C., Lo, Albert, Sims, John R., Mintun, Mark A.

Volltext

P3‐026: IMPLEMENTATION OF DUAL‐PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE‐AD CLINICAL TRIAL von Shcherbinin, Sergey, Hesterman, Jacob, Devous, Michael D., Natanegara, Fanni, You, Wenqi, Evans, Cynthia Duggan, Collins, Emily C., Lo, Albert, Sims, John R., Mintun, Mark A.

Volltext

P1‐048: PLASMA NF‐L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE‐AD STUDY von Wang, Hong, Charil, Arnaud, Shcherbinin, Sergey, Natanegara, Fanni, Chao, Georgia, Evans, Cynthia Duggan, Dage, Jeffrey, Irizarry, Michael C., Lo, Albert, Sims, John R.

Volltext

Donanemabの臨床開発とバイオマーカー：第II相試験におけるアミロイドプラーク量の変化 von 佐藤, 祥一郎

Volltext

3 Donanemabの臨床開発とバイオマーカー : 第II相試験におけるアミロイドプラーク量の変化 von 佐藤祥一郎, Sergey Shcherbinin, Scott W Andersen, Cynthia Duggan Evans, Albert Lo, Ming Lu, Michael Navitsky, Emily C Collins, John R Sims, Dawn A Brooks, Mark A Mintun

Volltext

Donanemabの臨床開発とバイオマーカー：第II相試験におけるアミロイドプラーク量の変化 von 佐藤, 祥一郎

Volltext